GlassScriptPhysician profile
Caitlin E Miller
NPI 1497169775
$2,086.87
in general payments reported to CMS, 2019-2025
22 companies · $656 in 2025
The $656 reported for 2025 was more than what 81% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $397 · 2022: $210 · 2023: $472 · 2024: $352 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.93 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $394.63 | 2023 | Puraply |
| Glaxosmithkline, LLC. | $221.64 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Bard Peripheral Vascular, INC. | $195.78 | 2022-2025 | Venclose Maven Catheter |
| Astrazeneca Pharmaceuticals LP | $186.16 | 2024-2025 | Breztri, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.31 | 2021-2025 | Jascayd |
| Mylan Specialty L.P. | $165.47 | 2021-2024 | Yupelri |
| Insmed, INC. | $104.03 | 2025 | Brinsupri, Arikayce |
| Actelion Pharmaceuticals US, INC. | $86.88 | 2021-2024 | Uptravi, Opsumit |
| Abbott Laboratories | $74.01 | 2022-2023 | Ensite Precision, Viewmate |
| Viatris Specialty LLC | $66.83 | 2025 | Yupelri |
| Csl Behring | $53.48 | 2025 | Kcentra, Haegarda |
| Amgen INC. | $49.53 | 2022-2024 | Tezspire |
| Grifols USA, LLC | $46.66 | 2024-2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $45.91 | 2022-2024 | Capvaxive |
| Solventum Corporation | $41.24 | 2025 | V.A.C. Dermatac, Promogran Prisma, Activ.A.C. |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $34.34 | 2021 | |
| Abbvie INC. | $31.17 | 2021 | |
| Shionogi INC | $27.99 | 2025 | Fetroja |
| United Therapeutics Corporation | $23.53 | 2024 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $22.46 | 2024 | Glassia |
| Advanced Respiratory, INC | $16.88 | 2021 | |
| Mallinckrodt Hospital Products INC. | $15.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.